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AID is a cytidine deaminase essential for class switch
recombination and somatic hypermutation during the
humoral immune response. In this issue of Immunity,
Gourzi et al. (2006) show that AID also plays a critical
role in innate immunity to virally induced acute pro-B
cell leukemia.
For more than a generation, immunologists had been
captivated (some might say distracted) by the elegance
of adaptive immunity. Progress in understanding com-
binatorial diversity of antigen receptors, clonal selec-
tion, immune memory, and self-tolerance contributed
to a view that innate immunity was but a modestly effec-
tive stop-gap measure until the antigen-specific lym-
phocytes arrived to save the day. The argument was
made that given the rapid rate of microbial evolution, in-
nate immunity was forever destined to be out-gunned.
Recently, however, we’ve been dazzled by the discov-
ery of a growing array of innate defense mechanisms
that recognize and attack microbes at levels inaccessi-
ble to the adaptive immune system, and we have
achieved a deeper appreciation of the myriad of intri-
cate interactions between the two. Interferons, for ex-
ample, activate innate viral defense mechanisms and
enhance responses of T cells specific for virally infected
cells. Recently, a family of enzymes known as cytidine
deaminases, originally discovered due to their ability
to edit cellular RNA molecules, was found to play a
key role in innate immunity to virus infection as well as
more globally in the adaptive humoral immune response
(Turelli and Trono, 2005). And now, as reported in this
issue of Immunity by Gourzi et al. (2006), one member
of this family appears to provide a first line of defense
against a cancer-causing retrovirus (Figure 1).
The initial discovery of a role for cytidine deaminases
in antiviral immunity came from ground-breaking stud-
ies by Malim and colleagues on HIV (Sheehy et al.,
2002). The HIV genome encodes a protein, vif (viral in-
fectivity factor), which is essential for its ability to infect
most target cells. Sheehy et al. used subtractive cDNA
cloning to identify the missing gene in a mutant T cell
line which could be infected by a vif-deficient virus.
This gene, initially named CEM15, was found to encode
APOBEC3G, a paralog of the cytidine deaminase
APOBEC1, an RNA editing enzyme. Subsequent work
revealed that vif targeted APOBEC3G for ubiquitin-
dependent degradation, preventing its inclusion in
virions (Sheehy et al., 2003). The idea was that
APOBEC3G, through its deaminase activity, would inac-
tivate virus by introducing a large number of C-to-U
modifications in the minus strand of viral cDNA. These
modifications would either destroy the reverse tran-
script or introduce debilitating numbers of point muta-
tions. HIV had evolved a way to evade this newly appre-
ciated innate defense mechanism and perhaps evenuse it to enhance the rate of its own evolution. In short
order, several groups replicated these results and ex-
tended them to show the involvement of APOBEC3G
in the cellular response to retroviruses in general and
possibly other classes of RNA viruses such as HBV
(Turelli and Trono, 2005).
This was not the first surprising example of the in-
volvement of cytidine deaminases in immunity. Several
years earlier, Honjo and colleagues discovered that an-
other APOBEC family member, activation-induced cyti-
dine deaminase, or AID, was necessary for both somatic
hypermutation (SHM) and class switch recombination
(CSR) (Muramatsu et al., 2000). They found AID among
a set of genes activated when B cells are treated with
cytokines and LPS to induce CSR in vitro. Remarkably,
the AID gene mapped to the site of an inherited human
immunodeficiency disease, HIGM2, and was mutated
in patients with the disease (Revy et al., 2000). These
patients lack immunoglobulin (Ig) isotypes other than
IgM and IgD and fail to undergo affinity maturation by
SHM during an immune response. A targeted mutation
in the AID gene duplicates the human disorder in
experimental mice. Although there is still some debate
in the field, the predominant view is that AID activates
both CSR and SHM by the direct deamination of cyto-
sine residues in genomic DNA, leading to DNA breaks
and either recombination or error prone repair. It is this
ability of AID to cause genomic DNA damage that un-
derlies the remarkable observations made in the current
report from Papavasiliou and colleagues (Gourzi et al.,
2006).
Gourzi et al. ask whether AID, like other APOBEC fam-
ily members, might play a role in the host response to
viral infection. Abelson murine leukemia virus (A-MuLV)
is a defective retrovirus that does not replicate in in-
fected cells. Instead, it transforms murine pro-B cells
in vitro and causes acute pro-B cell leukemia in vivo
by transducing the v-Abl oncogene (Rosenberg, 1982).
Gourzi et al. found that AID-deficient bone marrow
(BM) cells infected with A-MuLV were more susceptible
to transformation, resulting in increased number and
size of transformed foci as compared to wild-type BM
cells in vitro. Because death of infected wild-type and
AID-deficient BM cells was identical, the authors con-
clude that AID functions to restrict proliferation of in-
fected cells. Animal experiments revealed far more
rapid death due to fulminate leukemia of mice injected
with infected AID-deficient BM cells as compared to
mice infected with wild-type BM cells. Gourzi et al. went
on to show that A-MuLV induces AID transcription in
infected pro-B cells but to an amount lower than that
found in mature germinal center B cells undergoing
CSR. Unlike APOBEC3G, AID does not deaminate the
viral genome but instead activates somatic mutation in
infected cells as demonstrated by the appearance of
mutations in both Ig and l5 loci. The authors propose
that host genome damage caused by AID expression
is key to its protective effect. They showed that infected
cells activate a Chk1-dependent genotoxic stress
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Cytidine deaminases (CDAs), long known to be involved in nucleotide salvage pathways, have more recently been found to play key roles in gene
expression, anti-viral immunity, and immunoglobulin gene diversification (SHM, somatic hypermutation; CSR, class-switch recombination). Vif is
an HIV gene product which interferes with APOBEC3 activity.pathway observed in other transformed cells, resulting
in cell cycle arrest and upregulation of the NK cell acti-
vating ligand Rae-1 (Gasser et al., 2005). Thus, AID acti-
vation would slow infected cell growth and make the
cells targets for NK cell killing.
Although this new study uncovers an unexpected role
for AID in innate immunity, it is at first glance hard to rec-
oncile with our current understanding of the function of
AID in germinal center B cells where it is abundantly ex-
pressed. Why doesn’t AID expression cause genotoxic
stress in germinal center B cells, restricting B cell prolif-
eration and increasing their susceptibility to NK cell ly-
sis? According to the authors, Rae-1 is indeed induced
in germinal center B cells. One possibility is that cell cy-
cle arrest due to the action of p53 may be prevented by
the germinal center B cell transcription factor Bcl-6,
which was recently shown to interfere with p53 activa-
tion (Phan and Dalla-Favera, 2004). Because Bcl-6 is
not expressed in pro-B cells, AID induction should more
readily lead to cell cycle arrest and apoptosis in
A-MuLV-infected pro-B cells. It is worth noting in this re-
gard that about 50% of Abl-transformed pro-B cell lines
contain p53 mutations (Unnikrishnan et al., 1999). In re-
gards to NK cell lysis, it may be relevant that suscepti-
bility to NK killing depends on the ratio of inhibitory
and activating ligands on target cells. Transformed cells
often show diminished expression of MHC-I molecules,
the main inhibitory ligand for NK cells. Perhaps germinal
center B cells express sufficient MHC-I to prevent
NK cell killing regardless of Rae-1 induction, whereas
A-MuLV-infected cells might lose MHC-I expression
favoring NK cell killing.
The in vivo data in Gourzi et al. represent compelling
evidence that AID serves a protective role against
A-MuLV-induced pro-B cell leukemia. However, it is still
not clear whether this protection is mediated by NK cell
activation, Chk1 induced cell cycle arrest or some other
unsuspected mechanism. As the authors point out,
animal experiments involving either NK cell depletion orRae-1 antibodies to block ligand-receptor interactions
will be required to confirm the role of NK cells in A-MuLV
immunity. Additionally, it will be interesting to determine
whether AID or other APOBEC family members play
a role in host defense against different cancer-causing
viruses. Alternatively, as suggested by others, genomic
instability is a common feature of transformed cells,
which may lead to NK cell activating ligand expression
independent of APOBEC expression (Gasser et al.,
2005). Finally, these results pose the interesting evolu-
tionary question of whether two of the most elegant
mechanisms of adaptive immunity, CSR and SHM, actu-
ally evolved from a component of innate immunity.
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